Trump administration proposes a Medicare and Medicaid pilot to cover GLP-1 weight loss drugs, highlighting access benefits alongside fraud and regulatory oversight challenges.

CMS plans a voluntary five-year trial allowing state Medicaid and Medicare Part D plans to cover GLP-1 weight management drugs, including Ozempic and Wegovy, starting in 2026-27 amid pricing and coverage challenges.

Medicare faces evolving opportunities and challenges in covering weight loss drugs through legislation like the Treat and Reduce Obesity Act and federal demonstration projects. Drug adherence and cost-effectiveness remain key issues.

Recent Republican-led legislative changes delay Medicare drug price negotiations for costly cancer treatments, maintaining high patient costs and impacting seniors and disabled Americans.

CMS is considering a pilot program to cover GLP-1 drugs for obesity under Medicare and Medicaid, reversing earlier policy. This evolving coverage changes obesity drug access for patients and payers.

The Trump administration proposes a Medicare and Medicaid pilot program for covering GLP-1 weight loss drugs, marking a key shift in healthcare policy and potential budget impacts.

The Supreme Court's 2025 ruling affirms ACA preventive service coverage, shaping pharmaceutical, diagnostic, and insurance sector investments amid evolving HHS regulations.

Novo Nordisk expands access to Wegovy with a new self-pay pricing program and pursues legal actions against unauthorized compounded drug sales, impacting the obesity treatment market.

Pfizer and other pharmaceutical firms have discussed most-favored-nation drug pricing with the U.S. government, highlighting potential impacts on insurance and payer strategies.

CMS excludes obesity drugs from 2026 Medicare coverage, citing cost concerns; Eli Lilly criticizes the decision impacting obesity management treatments.